A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody response among people living with HIV who didn't respond to prior vaccination.

The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.

Deaths from HIV/AIDS are ten times lower than at the peak of the epidemic, and new research could drive that down even more.

HIV Vaccine Trials Network external relations program manager Dr. Daniel Driffin spoke at the 2024 White House World AIDS Day ...

A drug used to treat HIV that has also shown promise in preventing infections is not a cure for those already infected, as ...

A new study has found that a twice-yearly injection of lenacapavir can reduce the risk of HIV by 96%.

A new injectable drug for HIV prevention, lenacapavir, is being hailed as a potential game-changer in the fight against the ...

Twice-yearly injectables might soon be available to help prevent HIV infection. The injectable Sunlenca is even more ...

A twice-yearly shot could end AIDS, but will it reach everyone who needs it? Gilead's HIV prevention drug is 100% effective ...

The U.S. Centers for Disease Control and Prevention is seeking comment on a proposal to change the recommendations on HIV testing in doctors’ offices across the nation.